NCT04270058View on ClinicalTrials.gov

TEGSEDI Pregnancy Surveillance Program

Not yet recruitingOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

November 15, 2030

Study Completion Date

November 15, 2030

Conditions

Hereditary Transthyretin-mediated Amyloidosis With PolyneropathyPregnancy

Interventions

DRUG

inotersen

TEGSEDI injection, for subcutaneous use

Sponsors

Lead Sponsor

Akcea Therapeutics

All Listed Sponsors

lead

Akcea Therapeutics

INDUSTRY